A Randomized Phase II clinical trial assessing the Efficacy and Safety of MK-3475 (pembrolizumab) in combination with carboplatin and gemcitabine in patients with metastatic triple negative breast cancer
Administered By
Awarded By
Contributors
- Force, Jeremy M Principal Investigator
Start/End
- September 20, 2018 - September 30, 2022